U.S. President Donald Trump heads to Pittsburgh, Pennsylvania on Friday to headline a rally to celebrate Nippon Steel's ...

Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

A disruption in federal funds has jeopardized HIV testing and outreach in Mississippi, and researchers warn of a resurgence of the epidemic in the South.

Recent years have seen a 12 percent decline in new HIV infections. Cuts to federal funding could upend that progress.

Gilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, ...

Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.